To assess the noninferiority, efficacy, and safety of degarelix in achieving and maintaining testosterone at castrate levels (≤0.5 ng/mL) in Korean patients (CS42) versus non-Asian patients with prostate cancer (PCa).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
A Phase III, open-label, multicenter, single-arm trial was conducted in Korean patients with PCa Degarelix was administered at a starting dose of 240 mg followed by monthly (28-day intervals) maintenance doses of 80 mg (240/80 mg dose regimen) for 7 months The results were compared with non-Asian patients receiving degarelix 240/80 mg in the CS21 study
The estimated difference in the cumulative probabilities of testosterone ≤0 5 ng/mL from Day 28 to Day 196 between the trials was -2 3% (96 7% in CS42 vs 99 0% in CS21) The lower limit of the 95% confidence interval was -5 5%, i e , above the predefined noninferiority limit of -10% and thus noninferiority was established Decreases in serum testosterone, prostate-specific antigen, and luteinizing hormone over time were similar in CS42 and CS21 There were no clinically significant differences in incidence of treatment-emergent adverse events (72% in CS42 vs 70% in CS21) and changes in clinical chemistry and hematology parameters between the two trials The most common adverse event was injection-site reaction
Overall, degarelix was effective and well tolerated in Korean patients Testosterone suppression was noninferior to that in non-Asian patients and safety findings were as would be expected for elderly men with PCa undergoing androgen deprivation therapy
Prostate international 2015 Feb 12 [Epub]
Dalsan You, Byung Ha Chung, Sang Eun Lee, Choung-Soo Kim
Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea , Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea , Department of Urology, Seoul National University Bundang Hospital, Seongnam, South Korea , Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea